The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A . The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.
本发明涉及在结构上与
环孢素 A 相似的
环孢素类似物的异构体混合物。 与单个异构体相比,与天然存在的和其他目前已知的
环孢素和
环孢素衍
生物相比,这些混合物具有更强的疗效和更低的毒性。本发明的实施方案针对的是被称为 I
SATX247 的
环孢素 A 类似物的顺式和反式异构体及其衍
生物。与天然存在的和目前已知的
环孢素相比,I
SATX247 异构体的混合物具有增强药效和降低毒性的双重作用。I
SATX247 异构体以及烷基化、芳基化和氚化衍
生物是通过立体选择性途径合成的,其中反应的特定条件决定了立体选择性的程度。立体选择性途径可利用维蒂希反应或含有
硼、
硅、
钛和
锂等无机元素的有机
金属试剂。以混合物的总重量为基准,混合物中异构体的比例范围为:(E)-异构体约占重量的 10%至 90%,(Z)-异构体约占重量的 90%至 10%。